title: [A case of disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation caused by advanced colon cancer successfully treated with SOX/bevacizumab].
abstract: Our patient was a 58-year-old man who was diagnosed with a large bowel obstruction caused by ascending colon cancer, together with multiple liver metastases for which a right hemicolectomy was performed. After the operation, he developed disseminated intravascular coagulation(DIC)and severe anemia. Bone marrow biopsy findings led to a diagnosis of disseminated carcinomatosis of the bone marrow caused by colon cancer. We administered S-1+oxaliplatin(SOX) and bevacizumab( BV)chemotherapy, which improved the DIC. The patient was discharged from the hospital. After a total of six courses of chemotherapy, the carcinoma became resistant. We changed the drug regimen and his clinical condition improved. He survived for 292 days from the onset of disease.
authors.affiliation: Dept. of Surgery, Yao Tokushukai General Hospital.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Suzuki
authors.forename: Nobuko
authors.initials: N
authors.lastname: Matsuoka
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ushimaru
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Kakimoto
authors.forename: Akira
authors.initials: A
authors.lastname: Toyoda
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Endo
authors.forename: Osamu
authors.initials: O
authors.lastname: Murakami
authors.forename: Yasuro
authors.initials: Y
authors.lastname: Kato
authors.forename: Masafumi
authors.initials: M
authors.lastname: Inoue
authors.forename: Takuya
authors.initials: T
authors.lastname: Kimura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasakabe
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D019046:Bone Marrow Neoplasms / Q000188:drug therapy* / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D004338:Drug Combinations; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D000068258:Bevacizumab; D010094:Oxonic Acid